News for Tyra Biosciences, Inc. (TYRA)

An important meeting organized by Oppenheimer is set to take place on June 4. During this gathering, investors will have the chance to delve into various insigh

Tyra Biosciences (TYRA) has recently been assigned a new analyst rating by Piper Sandler, a prominent investment bank. On May 21, 2025, the firm announced an "O

PR NewswireCARLSBAD, Calif., May 12, 2025 CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnol

Tyra Biosciences (TYRA) to participate in three major investor conferences in May and June 2025. The company will feature a fireside chat and one-on-one

As of the end of March 2025, Tyra Biosciences (TYRA) held $318.9 million in cash, cash equivalents, and marketable securities. This financial position is projec

PR NewswireCARLSBAD, Calif., May 8, 2025 - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -- Initiated patient dosing in

Cash Position: Ended Q1 2025 with $318.9 million in cash, cash equivalents, and marketable securities, providing a runway through at least 2027.Research and De

Tyra Biosciences reports Q1 GAAP EPS of -$0.47. With $318.9M in cash reserves, the company is well-positioned to execute its plans through 2027.

Strong cash position of $318.9 million ensures funding through 2027. Multiple clinical trials advancing, including TYRA-300, TYRA-200, and TYRA-430.

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday. Shares of Northrop Grumman Corporation NOC shares fell ...

Shares of Calix, Inc. CALX rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued st...

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. ( NAMS or ”œNewAmsterdam” or the ”œCompany”), a

Shares of WaFd, Inc. WAFD rose sharply in today's pre-market trading following second-quarter results. WaFd posted quarterly GAAP EPS of 65 cents, beating mark...

Shares of Penguin Solutions, Inc. PENG rose sharply in today's pre-market trading after the company posted better-than-expected results for its second quarter o...

PR NewswireCARLSBAD, Calif., March 27, 2025 - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -- TYRA-300 to be evaluated in

Cash Position: Ended 2024 with $341.4 million in cash, cash equivalents, and marketable securities, up from $203.5 million in 2023, ensuring a financial runway

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Incyte Corporation INCY fell sharply in today's...

Shares of Precision BioSciences, Inc. DTIL rose sharply in today's pre-market trading. Precision BioSciences reported clearance of investigational new drug app...

Tyra Biosciences' TYRA-300 shows promise as an FGFR3 inhibitor with fewer side effects, but mixed market reactions spotlight FGFR1/2 concerns. See more here.